Search results
Found 6977 matches for
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
©
Credit: University of Oxford, John Cairns
Pioneering genomics approaches to develop targeted antisense oligonucleotides for treatment of patients with rare neurological disorders
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Development of antisense oligonucleotide and base editing therapeutics for neurodevelopmental haploinsufficiency disorders
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Predicting the therapeutic potential of all single gene disorders
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Addressing the health economic challenges of evaluating the full costs and effects of genome-targeted therapies
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Targeting Enhancers to Treat Neurological Diseases
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
In vivo reprogramming of Extracellular Vesicles for Targeted Drug Delivery of genome editors to the Central Nervous System
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Directed Evolution of Targeting Strategies for Precise Delivery of Genome Editors to Hematopoietic Stem Cells Using Extracellular Vesicles and Lipid Nanoparticles
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Peptide-mediated delivery of CRISPR-Cas genome editors in the eye
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Newborn Screening trial for Spinal Muscular Atrophy (SMA)
The aim of this population-based research study on newborn genetic screening for spinal muscular atrophy (SMA) is to evaluate the uptake and feasibility in the UK.
Hear from our students
What is it like to undertake a DPhil at the Department of Paediatrics? We asked some of the students here to share their interests, their projects and why they picked this department at the University of Oxford, over all others.
Clinical trials
This page contains information on all the clinical trials currently being undertaken by research groups within the Department of Paediatrics. All trials have a list of entry conditions called eligibility criteria. If you don’t meet these conditions, you won’t be able to join that trial but there may be other ones available for you. Please use the contact information in each listing to obtain further details of the trial.